Most candidate compounds for the treatment of AD are developed by targeting Aβ, tau, or inflammation, and small molecule compounds and monoclonal antibodies targeting amyloidogenic amyloid precursor protein (APP) processing and Aβ deposition are still the main candidates for the development of AD drugs. This evidence concerns the gene APP and Alzheimer disease.